Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isa-RVD Study in newly diagnosed multiple myeloma
2020-000946-32Phase 2Active
- Sponsor
- Cancer Trials Ireland
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Cancer Trials Ireland. Primary endpoint: VGPR or better rate at the end of two cycles of induction treatment. Started Jun 2020; status: active.
02
Drugs
isatuximablenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-000946-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000946-32.